C07D 403/14
Containing three or more hetero rings
Official title: containing three or more hetero rings
C07D403/14 (Containing three or more hetero rings) appears on 5,194 US grants and 7,202 published applications in this corpus.
Search patents in C07D- Granted patents
- 5,194
- Published applications
- 7,202
- Assignees
- 2,055
- Inventors
- 17,423
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 3 | 0 |
| 1978 | 3 | 0 |
| 1979 | 2 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 1 | 0 |
| 1983 | 2 | 0 |
| 1984 | 3 | 0 |
| 1985 | 8 | 0 |
| 1986 | 6 | 0 |
| 1987 | 8 | 0 |
| 1988 | 10 | 0 |
| 1989 | 9 | 0 |
| 1990 | 12 | 0 |
| 1991 | 15 | 0 |
| 1992 | 28 | 0 |
| 1993 | 27 | 0 |
| 1994 | 24 | 0 |
| 1995 | 27 | 0 |
| 1996 | 37 | 0 |
| 1997 | 38 | 0 |
| 1998 | 43 | 0 |
| 1999 | 42 | 0 |
| 2000 | 35 | 0 |
| 2001 | 35 | 5 |
| 2002 | 65 | 59 |
| 2003 | 78 | 119 |
| 2004 | 51 | 137 |
| 2005 | 48 | 153 |
| 2006 | 95 | 153 |
| 2007 | 93 | 197 |
| 2008 | 88 | 190 |
| 2009 | 99 | 248 |
| 2010 | 156 | 294 |
| 2011 | 148 | 293 |
| 2012 | 202 | 287 |
| 2013 | 249 | 335 |
| 2014 | 309 | 295 |
| 2015 | 282 | 369 |
| 2016 | 270 | 360 |
| 2017 | 307 | 380 |
| 2018 | 287 | 340 |
| 2019 | 300 | 367 |
| 2020 | 265 | 404 |
| 2021 | 274 | 370 |
| 2022 | 254 | 365 |
| 2023 | 231 | 495 |
| 2024 | 206 | 387 |
| 2025 | 253 | 349 |
| 2026 | 165 | 251 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- PHD inhibitor compounds, compositions, and use6 Oct 2026US 12,753,161 B2Akebia Therapeutics, Inc.
- Intermediate of biliverdin, and preparation method and use thereof6 Oct 2026US 12,753,167 B2Wuhan Jianmin Dapeng Pharmaceutical Co., Ltd.
- 1,5-disubstituted 1,2,3-triazoles are inhibitors of RAC/CDC42 GTPases6 Oct 2026US 12,753,183 B2University of Puerto Rico
- Pharmaceutical composition for treatment or prevention of ischemic cardiovascular disease29 Sep 2026US 12,746,220 B2Industry-Academic Cooperation Foundation, Yonsei University
- Organic molecules for use in light-emitting devices29 Sep 2026US 12,747,210 B2Samsung Display Co., Ltd.
- Antidegradant bis(dihydro and tetrahydroquinoline) compounds and uses thereof8 Oct 2026US 2026/0308127 A1Flexsys IP Holdings, LLC
- Cdk2 inhibitors and methods of using same8 Oct 2026US 2026/0308145 A1Guangdong Touchstone Translational Research Institute Co., Ltd.
- Compounds for the degradation of mutant braf1 Oct 2026US 2026/0297060 A1C4 Therapeutics, Inc.
- Pyrazinecarboxamide analog compounds for use in treating cancer1 Oct 2026US 2026/0297064 A1Novapano LLC
- Aromatic substituent-containing (hetero) aryl-imidazole compound, and preparation method therefor and use thereof1 Oct 2026US 2026/0297065 A1Open Source Therapeutics
Most cited
By later US patents
- Intermediates useful for making 2,4-pyrimidinediamine compounds192US 7,060,827 B2Rigel Pharmaceuticals, Inc. · 2006
- Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds176US 7,122,542 B2Rigel Pharmaceuticals, Inc. · 2006
- 2,4-pyrimidinediamine compounds and their uses176US 7,557,210 B2Rigel Pharmaceuticals, Inc. · 2009
- Kinase inhibitors175US 6,831,175 B2Abbott Laboratories · 2004
- Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof170US 7,074,801 B1Eisai Co., Ltd. · 2006